Skip to main content

full timeline

Capricor Duchenne therapy FDA review

The FDA has denied approval for Capricor Therapeutics' Duchenne muscular dystrophy cell therapy for a second time, citing serious data integrity violations in its Phase 3 trial.

Factlen Newsroom· Updated

Follow Capricor Duchenne therapy FDA review in the Factlen app and get an alert when there is news. Get the app

The FDA issued a rare public statement detailing data integrity violations in the clinical trial for Capricor's cell therapy.From: FDA Rejects Capricor's Duchenne Cell Therapy, Citing Serious Data Integrity Violations

Share this story

Latest report

FDA Rejects Capricor's Duchenne Cell Therapy, Citing Serious Data Integrity Violations

The FDA has denied approval for Capricor Therapeutics' Duchenne muscular dystrophy cell therapy for a second time, citing serious data integrity violations in its Phase 3 trial. The agency's unusual public rebuke leaves the treatment's future in the United States highly uncertain.

  • The FDA rejected Capricor Therapeutics' cell therapy deramiocel for a second time, citing serious data integrity violations in the Phase 3 HOPE-3 trial.
  • Regulators flagged unauthorized post-hoc changes to the statistical analysis plan and violations of study blinding procedures that render the data unreliable.
  • Capricor maintains that the trial met its primary endpoints, demonstrating a 54 percent slowing of upper limb decline in patients with Duchenne muscular dystrophy.
  • The unusual public rebuke from the FDA caused Capricor's stock to plummet nearly 80 percent, leaving the U.S. regulatory pathway for the drug highly uncertain.

The U.S. Food and Drug Administration has issued a second Complete Response Letter denying approval for deramiocel, an experimental cell therapy for Duchenne muscular dystrophy. The November 20 decision arrived two days ahead of the agency’s scheduled action date. It marks another significant regulatory setback for the treatment's developer, Capricor Therapeutics.[1][2]

In a highly unusual move, the regulatory agency accompanied the rejection with a public statement detailing its findings. The FDA disclosed that a Bioresearch Monitoring Program inspection uncovered serious data integrity violations during the pivotal Phase 3 HOPE-3 clinical trial. These issues ultimately compromised the reliability of the submitted evidence.[1][3]

The agency cited unauthorized post-hoc changes to the statistical analysis plan and violations of study blinding procedures. According to the FDA, these protocol breaches render the trial data fundamentally unreliable. The statement emphasized that the identified deficiencies are incapable of being remediated after the fact.[1][4]

"Upholding rigorous evidentiary standards is precisely how the FDA protects patients, particularly those living with rare diseases, from interventions whose benefits have not been sufficiently established," the agency stated. Regulators concluded that the current evidence simply does not meet the statutory threshold required for market approval.[1][4]

Capricor Therapeutics immediately pushed back against the agency’s characterization of the clinical program. In a press release issued late Friday evening, the biotechnology company acknowledged the rejection but omitted any direct reference to the FDA’s specific data integrity accusations. The company maintained that its clinical findings remain robust.[2]

"We are deeply disappointed for the boys and young men living with Duchenne and their families," said Linda Marbán, Capricor’s chief executive officer. She noted that deramiocel had been evaluated in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, which the company asserts both met their primary endpoints.[2]

The timeline of Capricor Therapeutics' regulatory efforts for deramiocel.

"We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval," Marbán added. The company stated it is reviewing the Complete Response Letter carefully and will outline its next operational steps once that evaluation is complete.[2]

A Shift in Clinical Focus

The recent rejection follows a turbulent regulatory review period that included a major strategic pivot by Capricor. The company originally sought approval for deramiocel to treat DMD-associated cardiomyopathy. However, a July 2026 advisory committee meeting proved highly critical of the cardiac data, resulting in a 9-3 vote against the therapy's effectiveness.[3][5]

Following that negative panel vote, Capricor amended its Biologics License Application to focus on a narrower indication: the preservation of upper limb function. This adjustment pushed the FDA's target review date to November 22. The revised application relied heavily on skeletal muscle data extracted from the HOPE-3 trial.[4][5]

The HOPE-3 study enrolled 106 patients with advanced Duchenne muscular dystrophy. According to Capricor’s previously reported topline results, participants receiving deramiocel demonstrated a 54 percent slowing of decline on the Performance of the Upper Limb version 2.0 scale compared to the placebo group over a 12-month period.[2][5]

Despite these reported figures, FDA reviewers consistently disputed whether the trial actually met its prespecified endpoints under the original statistical analysis plan. The agency argued that the results were highly sensitive to how missing data were handled, amplifying concerns about the modifications made after the randomized portion concluded.[5]

Mechanism and Prior Setbacks

Deramiocel, also known as CAP-1002, consists of allogeneic cardiosphere-derived cells. These specialized donor-derived heart cells are designed to secrete extracellular vesicles called exosomes. In preclinical models, these exosomes target macrophages to exert immunomodulatory and anti-fibrotic effects, theoretically preserving both cardiac and skeletal muscle function in dystrophy patients.[2]

This week's decision represents the second time the FDA has formally rejected the cellular medicine. In July 2025, the agency issued its first Complete Response Letter, citing insufficient evidence to establish the therapy's effectiveness for cardiomyopathy. That initial rejection also highlighted unresolved deficiencies regarding chemistry, manufacturing, and controls.[3][4]

At the time of the 2025 rejection, Capricor claimed to have been blindsided by the ruling, arguing that it had already submitted materials addressing the manufacturing concerns. The company stated that the FDA had simply not reviewed those documents due to the timing of the letter's issuance.[3]

Capricor Therapeutics shares plummeted nearly 80 percent in after-hours trading following the FDA's public rebuke.

Market Reaction and Future Pathways

The financial fallout from the FDA’s latest public rebuke was immediate and severe. Shares of Capricor Therapeutics crashed nearly 80 percent in after-hours trading on Friday. The stock plummeted from a closing price of $7.59 down to $1.63 per share as investors digested the damning regulatory assessment.[3]

Despite the market collapse, Capricor reported holding approximately $198.5 million in cash, cash equivalents, and marketable securities as of September 30. The company indicated that this capital reserve should be sufficient to fund its planned operations for at least the next 12 months while it determines a path forward.[2]

With the United States regulatory pathway now severely compromised by the data integrity findings, the company is reportedly exploring alternative markets. Recent corporate updates suggest Capricor is initiating discussions regarding potential regulatory submissions in Europe and Japan, though those efforts remain in the preliminary stages.[5]

The FDA has also issued a separate Regulatory Responsibility Letter tied directly to its inspection observations. Capricor will have a formal opportunity to respond to these specific clinical conduct findings, though the agency's public statement explicitly noted that the underlying data cannot serve as a reliable foundation for approval.[1][2]

Implications for Rare Disease Development

The deramiocel saga highlights the escalating tension between regulatory evidentiary standards and the urgent unmet needs of the rare disease community. Duchenne muscular dystrophy is a devastating, progressive neuromuscular disorder that typically affects young boys, leading to severe muscle wasting, loss of independence, and premature death.[4][5]

Patient advocacy groups and clinical investigators have consistently pushed for greater regulatory flexibility for DMD treatments. More than two dozen trial investigators and physicians recently penned a letter to the FDA supporting deramiocel's approval, emphasizing the extraordinary clinical value of slowing skeletal muscle disease progression by any measurable margin.[3]

Illustration: Deramiocel was being evaluated for its potential to preserve upper limb function in patients with advanced Duchenne muscular dystrophy.

However, the FDA’s forceful public statement signals a strict boundary regarding clinical trial conduct. By explicitly calling out unblinding violations and post-hoc statistical changes, the agency is reinforcing that flexibility in rare disease approvals does not extend to compromising fundamental data integrity protocols.[1][4]

The rejection leaves older and more severely affected DMD patients with limited therapeutic options. While several gene therapies and exon-skipping drugs have reached the market in recent years, many are restricted to specific genetic mutations or younger ambulatory age groups, leaving a significant gap in the treatment landscape.[3]

For Capricor, the immediate challenge involves addressing the Regulatory Responsibility Letter and deciding whether to conduct a completely new Phase 3 trial. Given the FDA's assertion that the HOPE-3 data cannot be remediated, salvaging the U.S. application without fresh, rigorously controlled clinical evidence appears highly improbable.[1][4]

The broader biotechnology sector is likely to view the FDA's detailed public disclosure as a warning. The agency rarely comments on Complete Response Letters with such specificity, typically allowing companies to frame the rejections themselves. This departure underscores the severity with which regulators viewed the trial's execution.[3][4]

Sources

  1. [1]U.S. Food and Drug Administration — FDA Statement on Complete Response Letter for Deramiocel Read on U.S. Food and Drug Administration →
  2. [2]Capricor Therapeutics — Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy Read on Capricor Therapeutics →
  3. [3]BioPharma Dive — In an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel's second rejection since 2025 Read on BioPharma Dive →
  4. [4]Endpoints News — Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial Read on Endpoints News →
  5. [5]Neurology Live — FDA Issues Second Complete Response Letter for Deramiocel in Duchenne Muscular Dystrophy Read on Neurology Live →

Key numbers

Slowing of heart dysfunction progression
91%
Slowing of upper limb muscle decline
54%
Patients enrolled in the HOPE-3 trial
106
Patients experiencing manageable allergic reactions
42%

From: Landmark Cell Therapy Trial Shows 91% Preservation of Heart Function in Duchenne Muscular Dystrophy

How the story developed

Deramiocel is an investigational cell therapy developed by Capricor Therapeutics for patients with advanced Duchenne muscular dystrophy. The treatment utilizes cardiosphere-derived cells sourced from healthy donor hearts, which are intended to reduce inflammation and scarring in damaged muscle tissue.

On August 3, by 12:18 UTC, results from a Phase 3 clinical trial were published in The Lancet. The data indicated that the therapy significantly slowed the progression of the disease, showing a 91 percent reduction in the rate of heart dysfunction.

Phase 3 trial data showed significant preservation of both cardiac and skeletal muscle function.From: Landmark Cell Therapy Trial Shows 91% Preservation of Heart Function in Duchenne Muscular Dystrophy ·

Prior to the publication, an FDA advisory committee voted against the efficacy of the therapy. The committee based its decision on statistical concerns regarding the trial data.

Following the advisory committee's vote, the FDA was scheduled to make a final decision on the approval of the therapy by August 22.

Unlike treatments that target genetic mutations, cell therapy aims to halt the downstream inflammation that destroys muscle tissue.From: Landmark Cell Therapy Trial Shows 91% Preservation of Heart Function in Duchenne Muscular Dystrophy ·